| Literature DB >> 29931102 |
Joseph A Picoraro1, Dale Lee2, Caren A Heller3, Alandra Weaver3, Jeffrey S Hyams4, Laurie S Conklin5,6, Anthony Otley7, David Ziring8, Subra Kugathasan9, Joel R Rosh10, Andrew Mulberg11, Lee A Denson12, Michael D Kappelman13, Andrew B Grossman14, Athos Bousvaros15, K T Park16.
Abstract
The Crohn's & Colitis Foundation has facilitated transformational research in pediatric inflammatory bowel disease (IBD), through the RISK and PROTECT studies, that has laid the groundwork for a comprehensive understanding of molecular mechanisms of disease and predictors of therapeutic response in children. Despite these advances, children have lacked timely and informed access to the latest therapeutic advancements in IBD. The Crohn's & Colitis Foundation convened a Pediatric Resource Organization for Kids with Inflammatory Intestinal Diseases (PRO-KIIDS) Clinical Innovations Meeting at the inaugural Crohn's and Colitis Congress in January 2018 to devise how to advance the care of children with IBD. The working group selected 2 priorities: (1) accelerating therapies to children with IBD and (2) stimulating investigator-initiated research while fostering sustainable collaboration; and proposed 2 actions: (a) the convening of a task force to specifically address how to accelerate pharmacotherapies to children with IBD and (b) the funding of a multicenter clinical and translational research study that incorporates the building of critical research infrastructure.10.1093/ibd/izy205_video1izy205.video15799266615001.Entities:
Mesh：
Substances：
Year: 2019 PMID： 29931102 PMCID： PMC8133504 DOI： 10.1093/ibd/izy205
Source DB: PubMed Journal: Inflamm Bowel Dis ISSN： 1078-0998 Impact factor: 5.325